Clinical Correlates of Immunotherapy

• 6453 · PDF III-IV期黑色素瘤中IPI/NIVO/RELA联合sarilumab的血清药效学生物标志物:一项Simon II期试验的第1阶段结果(NCT05428007) Serum pharmacodynamic biomarkers of IPI/NIVO/RELA plus sarilumab in Stage III-IV melanoma: Stage 1 results of a Simon Phase II trial (NCT05428007) Teruyuki Mizutani, Amrutesh Puranik, Inderjit Mehmi, Judith Goldberg, Maya Dimitrova, Perla Arriola, Stanzin Idga, Xiaochun Li, Benjamin Levinson, Justine Cohen, Elizabeth I. Buchbinder, Donald Lawrence, Alissa Kalyan, Morgan Simons, F. Stephen Hodi, Ryan J. Sullivan, Omid Hamid, Michelle Krogsgaard, Janice M. Mehnert
• 6454 · PDF 单核细胞活化增强与T细胞细胞毒性是新辅助durvalumab联合吉西他滨-顺铂(D+GP)治疗局限性胆道癌(BTC)获益的基础：2期DEBATE研究 Enhanced monocyte activation and T cell cytotoxicity underlie the benefit of neoadjuvant durvalumab plus gemcitabine-cisplatin (D+GP) in localized biliary tract cancer (BTC): Phase 2 DEBATE study Changhoon Yoo, Hyung-Don Kim, Chang Yeon Kim, Joon Oh Park, Hyehyun Jeong, Kyu-Pyo Kim, Jung Yong Hong, Sang Hyun Shin, Tae Jun Song, Dongwook Oh, Woohyung Lee, Jae Hoon Lee, Dae Wook Hwang, Jeong Seok Lee
• 6455 · PDF 细胞毒性T细胞特征是高分化胃肠道神经内分泌肿瘤对177Lu-DOTATATE联合pembrolizumab治疗反应的基础 Cytotoxic T-cell signatures underlie therapeutic response to 177Lu-DOTATATE plus pembrolizumab in well-differentiated gastroenteric neuroendocrine tumors Naoki Mizutani, Shloka Shukla, Nicholas Fidelman, Bridget P. Keenan, David Y. Oh, Kira Chan, Li Zhang, Emily K. Bergsland, Thomas Hope, Lawrence Fong
• 6456 · PDF 抗PD(L)1为基础治疗优异反应外周生物标志物的泛肿瘤研究 Pan-tumor investigation of peripheral biomarkers of excellent response to anti-PD(L)1-based therapy Howard L. Li, Soren Charmsaz, Chester Kao, Carlotta Pazzi, Madelena Brancati, James Leatherman, Nicole E. Gross, Royce P. Lee, Xiyu Zhao, Christopher Thoburn, Jeannie Hoffman-Censits, Evan J. Lipson, Yasser Ged, Marina Baretti, G Scott Chandler, Rajat Mohindra, Laura Tang, Sanjay Bansal, Aditi Guha, Elizabeth Jaffee, Daniel J. Zabransky, Won Jin Ho, Mark Yarchoan, Mari Nakazawa
• 6457 · PDF STA551(STA)——一种肿瘤选择性CD137激动剂作为单药及与atezolizumab(atezo)联合应用并采用CD8 PET成像评估药效学效应的I期研究 Phase I study of STA551 (STA) a tumor-selective CD137 agonist, as monotherapy and in combination with atezolizumab (atezo) using CD8 PET imaging to assess pharmacodynamic effects Udai Banerji, Diogo Silva, Joshua Ting, Zoulikha Zair, Prakash Manoharan, Toshihiko Doi, Shigehiro Koganemaru, Noboru Yamamoto, Takafumi Koyama, Seiichi Ikeda, Yuki Kanai, Michiyasu Inatani, Hitomi Takeshita, Akiko Hashimoto, Yoshitaka Ogita, Yuma Takano, Kei Higashikawa, Fiona Thistlethwaite
• 6458 · PDF 利用肿瘤指导的B细胞受体进行肉瘤中的发现和基于抗体的免疫治疗 Harnessing tumor-informed B cell receptors for discovery and antibody-based immunotherapy in sarcoma Varshini Arunkumar, Manoj Chelvanambi, Joshua B. Plummer, Monika Zelazowska, Fabiana J. Veguilla, Elise Nassif Haddad, Noha M. Osman, Wei-Lien Wang, Davis Ingram, Khalida M. Wani, Angela Bhalla, Sharon M. Landers, Keila E. Torres, Jennifer A. Wargo, Bin Liu, Alexander Lazar, Neeta Somaiah, Christina L. Roland, Kevin McBride, Emily Z. Keung
• 6459 · PDF FL115——一种新型IL-15超级激动剂作为皮下注射用于癌症免疫治疗的开发 Development of FL115, a novel IL-15 superagonist, as subcutaneous injection for cancer immunotherapy Qinghua Wu, Quanxiao Li, Dong Wei
• 6460 · PDF 非小细胞肺癌中与免疫检查点抑制剂长期反应和耐药相关的免疫学和转录特征 Immunologic and transcriptional features associated with long-term response and resistance to immune checkpoint inhibitors in non-small cell lung cancer checkpoint inhibitors in non-small cell lung cancer Yoshihiro Masui, Tatsuya Yoshida, Jun Miyakoshi, Ryoko Higashiyama, Akiko Tateishi, Yuki Shinno, Tomonori Mizutani, Yusuke Okuma, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Yasushi Goto
• 6461 · PDF 对原发、非转移性高级别浆液性卵巢癌患者血浆样本进行全面的细胞因子、趋化因子和免疫标志物评估以估计结局和铂类耐药 Comprehensive cytokine, chemokine and immune marker evaluation in plasma samples of primary, non-metastatic high grade serous ovarian cancer patients to estimate outcome and platinum resistance Sabine Kasimir-Bauer, Buesra Eser, Yipeng Wang, Gordon Vansant, Stefanos I. Moukas, Rainer Kimmig, Fabinshy Thangarajah
• 6462 · PDF 基线外周免疫特征与黑色素瘤免疫治疗毒性相关 Baseline peripheral immune signatures associate with toxicity to immunotherapy in melanoma Iluja Gautam, Patricia Rayman, Nickolas Stabellini, Jennifer Powers, Adam Moen, Brian Race, Paul Pavicic, Mona Patel, Alberto J. Montero, C. Marcela Diaz-Montero
• 6463 6463 H3K27M突变型弥漫性中线胶质瘤中GD2-CAR T细胞治疗的纵向单细胞图谱揭示体液和细胞抗CAR免疫 Longitudinal single-cell atlas of GD2-CAR T cell therapy in H3K27M-mutant diffuse midline glioma identifies humoral and cellular anti-CAR immunity Yiyun Chen, Kun-Wei Song, Moksha H. Desai, Ying-Wen Huang, Nadya Iswari, Zachary J. Ehlinger, Hossein Daghagh, Maximilian R. A. Koch, Kevin Reynolds, Kelvin C. Mo, Kristin C. Y. Tsui, Skyler Rietberg, Mark P. Hamilton, Snehit Prabhu, Sonia Partap, Jasia Mahdi, Emily Egeler, Steven A. Feldman, Sabine Heitzeneder, Sean A. Yamada-Hunter, Elena Sotillo, Bita Sahaf, Zinaida Good, Michelle Monje, Sneha Ramakrishna, Crystal L. Mackall
• 6464 · PDF 手术诱导的髓源性抑制细胞扩增和细胞毒性淋巴细胞功能丧失可预测胰腺癌的不良生存 Surgery-induced expansion of myeloid-derived suppressor cells and loss of cytotoxic lymphocyte function predict poor survival in pancreatic cancer Olivia Johnsson, Malin S. Nilsson, Roberta Kiffin, Johan Bourghardt Fagman, Caroline Vilhav, Svein Olav Bratlie, Peter L J Naredi, Kristoffer Hellstrand, Anna Martner
• 6465 · PDF 使用细胞因子免疫评分验证原发性皮肤黑色素瘤中肿瘤浸润淋巴细胞的分类：解决服务不足人群中的生物标志物差异 Validating tumor-infiltrating lymphocyte classification in primary cutaneous melanoma using cytokine immune scores: Addressing biomarker disparities in underserved populations Meshack Bida, Rodney Hull, Thabiso Miya, Tebogo Marutha, Zodwa Dlamini
• 6466 · PDF leronlimab联合TAS-102和贝伐珠单抗治疗既往接受过治疗的转移性结直肠癌的一项2期研究的初步结果 Preliminary results of a phase 2 study of leronlimab in combination with TAS-102 and bevacizumab in previously treated metastatic colorectal cancer Pashtoon M. Kasi, Ari Baron, Arvind Chaudhry, Laura Tenner, Daniel L. Adams, Alexis B. Duffy, Hallgeir Rui, Patrick Vittner, Joseph Meidling, Jacob P. Lalezari
• 6467 · PDF 具有治疗诱导衰老样表型的骨髓瘤细胞与CAR-T治疗耐药相关 Myeloma cells with therapy-induced senescence-like phenotype are associated with resistance to CAR-T therapy Sofia Arbelaez, Andre De Menezes Silva Corraes, Gabriel Alvares Borges, Chen Wu, Christoph Schaefers, Malvika Gupta, Zuoyi Shao, Kevin Regan, Rayaan Kamal, Angelo Jose Guilatco, Neal I. Sannuli, Ying Li, Taxiarchis Kourelis, Wilson Gonsalves, Moritz Binder, Melinda Tan, Nadine Abdallah, Megan Weivoda, Yi Lin
• 6468 · PDF 通过RNA分析识别的乳腺癌中免疫特征的活检部位特异性差异 Biopsy site-specific variation in immune signatures identified by RNA profiling in breast cancer Smruthy Sivakumar, Ericka Ebot, Douglas I. Lin, Meagan Montesion, Jeffrey S. Ross, Lee A. Albacker, Garrett M. Frampton, Michelle Marie Williams, Ethan S. Sokol
• 6469 · PDF 微生物组稳定性的纵向丧失与肺癌和黑色素瘤对免疫检查点抑制剂的不良应答相关 Longitudinal loss of microbiome stability is associated with poor response to immune checkpoint inhibitors in lung cancer and melanoma Yujie Zhao, Jarushka Naidoo, Michael Conroy, Jacqueline T. Ferri, Joell J. Gills, Krista Y. Chen, James R. White, Sara Glass, Willaim O. Assan, Kimberly Peloza, Megan D. Schollenberger, William H. Sharfman, Kristen Marrone, Patrick M. Forde, Julie R. Brahmer, Valsamo (Elsa) Anagnostou, Drew M. Pardoll, Joseph Murray, Evan J. Lipson, Cynthia L. Sears, Fyza Y. Shaikh
• 6470 · PDF IL-18装甲型CD19 CAR T细胞对肿瘤微环境的空间重塑与复发或难治性淋巴瘤的持久缓解相关 Spatial remodeling of the tumor microenvironment by IL-18-armored CD19 CAR T cells is associated with durable remission in relapsed or refractory lymphoma Nakial C. W. Cross, Yael A. Day, Sonia Ndeupen, Vanessa E. Gonzalez, Zhen Miao, Sam I. Kim, Rachel M. Leskowitz, Amy Marshall, Julie K. Jadlowsky, Gabriela Plesa, Donald L. Siegel, Elizabeth O. Hexner, Jakub Svoboda, Stephen J. Schuster, Nancy R. Zhang, Joseph A. Fraietta, Andrew J. Rech, Carl H. June
• 6471 · PDF 省略MMF后的免疫相关性导致异基因干细胞移植中免疫重建加速而无移植物抗宿主病风险特征增加（OmitMMF试验） Immune correlates post MMF omission lead to accelerated immune reconstitution without increased graft versus host disease risk signatures for allogenic stem cell transplant (OmitMMF trial) Vanshika Chauhan, Joseph Lownik, Larry Milshteyn, Haein Kim, Ronald Paquette, Akil Merchant
• 6472 6472 肿瘤细胞NY-ESO-1表达预测NSCLC中PD-1/PD-L1阻断的不良应答 Tumor-cell NY-ESO-1 expression predicts poor response to PD-1/PD-L1 blockade in NSCLC Adele Lerue, Jean-Philippe Guegan, Christophe REY, Sophie Cousin, Benjamin Besse, Fabrice Barlesi, Christophe Massard, David Planchard, Alban Bessede, Antoine Italiano
• 6473 · PDF 克隆巩固和转录重编程界定对免疫检查点抑制剂耐药的非小细胞肺癌 Clonal consolidation and transcriptional re-programming define non-small cell lung cancers resistant to immune checkpoint inhibitors Natalie Vokes, Arvind Ravi, Mark M. Awad, Patrick M. Forde, Marta Luksza, Benjamin Dylan Greenbaum, Adam Jacob Schoenfeld, John V. Heymach, Alice T. Shaw, Pasi A. Jänne, Jedd D. Wolchok, Matt Hellman, Gad Getz, JUSTIN GAINOR
• 6474 · PDF 用于免疫治疗临床试验的稳健且精确的稀有事件分析 Robust and precise rare event analysis for immunotherapy clinical trials Chengsen Xue, Thomas W. Mc Closkey, Andew Roche
• 6475 · PDF 具有治疗诱导衰老样表型的骨髓瘤细胞对T细胞导向疗法的杀伤具有更高的耐药性 Myeloma cells with therapy-induced senescence-like phenotype have increased resistance to killing by T cell directed therapies Christoph Schaefers, Angelo Jose Guilatco, Sofia Arbelaez, Gabriel Alvares Borges, Chen Wu, Andre de Menezes Silva Corraes, Malvika Gupta, Zuoyi Shao, Kevin Regan, Rayaan Kamal, Neal I. Sannuli, Ying Li, Taxiarchis Kourelis, Wilson Gonsalves, Melinda Tan, Nadine Abdallah, Yi Lin, Megan Weivoda
• 6476 · PDF 通过CBM588调节微生物组可减弱接受双重免疫检查点阻断的转移性肾细胞癌患者的T细胞耗竭 Microbiome modulation via CBM588 dampens T cell exhaustion in patients with metastatic renal cell carcinoma on dual immune checkpoint blockade Colt A. Egelston, Miguel Zugman, Hedyeh Ebrahimi, Regina Barragan Carrillo, Nazli Dizman, Salvador Jaime-Casas, Xiaochen Li, Daniela V. Castro, Benjamin Mercier, Marice Alcantara, Motomichi Takahashi, Atsushi Hayashi, Tom Parks, Sumanta Kumar Pal, Peter P. Lee, Alexander Chehrazi-Raffle
• 6477 · PDF 胶质母细胞瘤中基于肽的肿瘤相关抗原疫苗：ETAPA I期临床试验的相关性结果 Peptide-based tumor-associated antigen vaccine in glioblastoma: Correlative results of the ETAPA Phase I clinical trial Elizabeth Owens, Kelly M. Hotchkiss, Pamela Norberg, Evan Buckley, Katayoun Ayasoufi, Stevie Threatt, Justin T. Low, Madison L. Shoaf, Melody Goldston, Kristen Batich, Margaret O. Johnson, James E. Herndon, Smita K. Nair, Kent Weinhold, Henry S. Friedman, David M. Ashley, Annick Desjardins, John H. Sampson, Mustafa Khasraw
• 6478 · PDF T细胞重编程的时间动态与转移性肾细胞癌基于ICI的联合治疗的临床反应相关 Temporal dynamics of T cell reprogramming associate with clinical response to ICI-based combination therapy in metastatic renal cell carcinoma KyuTae Hwang, Seowoo Kim, Mi Zhou, William Y. Kim, Minyong Kang
• 6479 6479 免疫治疗和微生物群干预作为间变性甲状腺癌的潜在治疗选择 Immunotherapy and microbiota interventions as potential treatment options for anaplastic thyroid cancer Jocelynn G. Colunga Minutti, Naimah Turner, Synat Keam, Roza Nurieva

在会议检索中浏览本分会场